🔥Telegram İfşa

Love it! 🙌 What a night with the best crew. #GiantsCC25 #ASCO2025

It’s today! See you tonight (Saturday, May 31st) at the Marriott Marquis! Let’s talk through what’s practice-changing at #ASCO25 with the experts and Oncology Brothers Narjust Florez, MD, FASCO #FlorezLab Arthur Aung ASCO Coral Olazagasti, MD Sandip Patel MD FASCO Abner Antonio Murray, MD PhD

Such a pleasure to meet with Oncology Brothers in person! Looking forward to learning from this incredible group. Oncology Brothers Narjust Florez, MD, FASCO Nehemias GR Petros Grivas Tanios Bekaii-Saab, MD Abner Antonio Murray, MD PhD OncLive.com #ASCO2025 ASCO

Amazing interview! Coral Olazagasti, MD Chinmay Jani

🎬 Behind the scenes at the Oncology Brothers x SignifyMD shoot with Chinmay Jani and @COLazagasti—filming this was a blast! 🔊 Sharp clinical insights, effortless chemistry, and plenty of laughs between takes. They dive into real-world #EGFR sequencing strategies and the evolving

Excited to join the GRACE team as an ambassador alongside Arthur Aung and Faith Abodunrin MD! Looking forward to contributing to #patient #education and empowering through knowledge.

The #NextWaveForum is a meaningful longitudinal connection with peers and mentors, helping shape our future as medical/thoracic oncologists. Grateful for the opportunity to catch up with everyone yesterday! Sarah Waliany, MD, MS Ben Bleiberg Anuja Abhyankar Ticiana Batista (Leal) Arthur Aung

Thanks so much, Abner Antonio Murray, MD PhD ! 🙏 Means the world to have your support. Grateful for friends who show up, cheer loud, and walk this journey with me through the hard work and the dream 💪🧠🚀 Big thanks to OncLive.com and BioAscend #NextWaveForum for bringing us together!

Huge thanks to my fellowship family for showing up and cheering me on during my presentation 🙌 Couldn’t do this without you all. Big shoutout to my mentor @DrSeetharamu for always believing in me. #ASCO2025 Nagashree Seetharamu Divya Chukkalore Adit Singhal, MD Northwell Health

Dr. Pasi Janne at #ASCO25 with update on KRYSTAL7: phase II study of first line adagrasib plus pembrolizumab for #KRAS G12C NSCLC. RR 44% (61% for PDL1 high). mDOR 26.3m, PFS 11m (27.7m for PDL1 high), OS 18.3m. 17% had to stop pembro for TRAE.

Proud to be an investigator in the head and neck cohort of SGN35-033. Our data was discussed today at ASCO, showing promising clinical efficacy of BV + Pembro in treatment -naive patients with metastatic HNSCC and CPS ≥1. meetings.asco.org/abstracts-pres… Nebraska Medicine UNMC Heme Onc

Amazing work for metastatic HNSCC—excited to see BV + Pembro showing promise in the frontline setting! Congrats to authors Omar Abu Ghanimeh @onclive #ASCO25 #HeadAndNeckCancer

Woohoo! So nice to see focus back on Head and neck cancer after a long time! Just about time #ascoplenary #NIVOPOSTOP ASCO #ASCO2025 significant DFS benefit. #hnscc

When I was born, cisplatin + RT had just become the post-op standard for high-risk LA-SCCHN. It has stayed that way for 30 years. As a fellow, it’s meaningful to witness real progress. Immunotherapy is finally entering. A new era is starting for #HNSCC #ASCO25

So good to reconnect with my SLU Medicine family at #ASCO25! Shoutout to Dr. Brian Abboud Brian Abboud future oncology fellow,and Nehemias Guevara-Rodriguez - an inspiring colleague who’s smart, driven, and full of heart. Grateful to learn and grow together. SLU Internal Medicine Residency Ravi Nayak, MD,FCCP, FRCP Fred Buckhold

Breaking in #LungCancer: FDA has approved taletrectinib (Ibtrozi) for adults with ROS1-positive NSCLC (locally advanced or metastatic) as of June 11 2025 A new targeted option joins the fight 📌 Developed by Nuvation Bio ASCO Arthur Aung Hem-Onc Fellows Network Abner Antonio Murray, MD PhD OncoDaily

Amazing job my friend! Nehemias Guevara-Rodriguez Narjust Florez, MD, FASCO

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

Amazing job Divya Chukkalore !

Grateful to work with Nagashree Seetharamu and colleagues on developing ICTIS. Clinical trial eligibility criteria often exclude patients with comorbidities or autoimmune disease. ICTIS score provides a standardized way to measure and track inclusivity in advanced NSCLC